Vibegron bulk supplier for pharma manufacturers

Vibegron 75 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 75 mg

Reference Brands: Gemtesa (USA), Obgemsa (EU/UK)

Vibegron is a selective β₃-adrenergic receptor agonist used to treat symptoms of overactive bladder (OAB) such as urinary urgency, frequency and urge urinary incontinence in adults (including men with BPH being treated). It works by relaxing the bladder’s detrusor muscle, increasing storage capacity and reducing incontinence episodes.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Vibegron? List it or send an offer →

Product Description:

Vibegron is a selective beta-3 adrenergic receptor agonist. Beta-3 receptors predominate in the detrusor muscle of the bladder, and stimulating them relaxes the muscle during filling, increasing bladder capacity and reducing urgency. It treats overactive bladder by a different route from antimuscarinics, and it avoids their dry mouth, constipation and cognitive effects — an important consideration in older patients.

It is used for overactive bladder with urge incontinence, urgency and frequency in adults, at 75 mg once daily without titration. Unlike mirabegron, the other beta-3 agonist, it has not been associated with a meaningful rise in blood pressure in trials and does not inhibit CYP2D6, which simplifies prescribing alongside other medicines. Urinary tract infection, headache and nasopharyngitis are the common adverse effects. Urinary retention can occur in bladder outlet obstruction or with antimuscarinic drugs.

Sourcing notes. Originator product, on patent, no generic. Developed in Japan, it is approved in the US and the EU under different brand names. Supply is through authorised distribution. It competes with mirabegron, which has generic entry in some markets, so price differences shape formulary decisions.

How Vibegron is supplied today, and licensing ahead of patent expiry

Vibegron is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Vibegron, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Vibegron supply →

Back to Listing

Frequently Asked Questions

Vibegron is used to treat overactive bladder (OAB) with symptoms such as urinary urgency, increased frequency, and urge urinary incontinence. It works by relaxing the bladder’s detrusor muscle, allowing it to hold more urine and reducing sudden urges to urinate.

Vibegron is made from the active ingredient vibegron, a selective beta-3 adrenergic receptor agonist that enhances bladder relaxation during the storage phase of the urinary cycle.

The trade name of Vibegron is Gemtesa.

Vibegron (Gemtesa) is developed and marketed by Urovant Sciences, a subsidiary of Sumitovant Biopharma and part of the Sumitomo Pharma Group.

The generic name is Vibegron.

The brand name is Gemtesa.

Vibegron is manufactured by Urovant Sciences in the United States and Japan under the quality and regulatory standards of the U.S. FDA and Japan’s PMDA.

Vibegron is sold as Gemtesa, Obgemsa and Beova. It is developed and sold by Sumitomo Pharma in the US, and by Kyorin in Japan, and by Pierre Fabre in Europe. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.